Lv3
385 积分 2022-03-24 加入
Top advances of the year: Sarcoma
12天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
13天前
已关闭
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
13天前
已完结
Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies
2个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
2个月前
已完结
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
2个月前
已完结
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
3个月前
已完结
The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients
3个月前
已完结
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
3个月前
已完结
皖公网安备34019202002308
